lation has mainly been ascribed to interactions between proteins and the noncoding portions of the mRNA itself. It has generally been thought that these proteins were solely responsible for control of translation. Now, evidence is mounting that miRNAs bind to these noncoding regions of mRNA and exert profound effects on protein synthesis and consequently cell functions. The implications for cancer are astonishing.
First discovered 14 years ago in Caenorhabditis elegans [2, 3] , a primitive worm, miRNAs may target at least one third of all mRNAs. On average, each of the approximately 600 miRNAs found in mammalian cells contains partial sequence homology to 100 -200 mRNAs. miRNAs have been implicated in the regulation of a diversity of processes, such as B-and T-cell development, antigen response, immune surveillance and tolerance, and other basic functions such as cell proliferation and death. In distinction to artificially synthesized small interfering RNAs, which target a single mRNA and cause its digestion by endonucleases, miRNAs target multiple mRNAs through partial sequence complementarity and function primarily by inhibiting protein translation (Fig. 1) . However, new work by a Yale team has added a new dimension, suggesting that, in synchronously replicating cells, miRNAs may reverse course and become stimulatory to RNA translation [4] .
Recent work from several laboratories has revealed that, in the development of lymphoid cells from undifferentiated precursors to mature antigen responders, specific miRNAs 
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The Oncologist 2008;13:1-3 www.TheOncologist.com appear at specific stages in development (reviewed in [5] ). The Rajewsky laboratory knocked out one of these miRNA genes (miR150), which stops B cells along their developmental pathway, and another miRNA gene (miR155) that demonstrates defects in plasma cells, the terminal stage of B-cell development. The Jacks laboratory knocked out another group of miRNA genes (miR-17-92 clusters). These mice demonstrated lung hypoplasia and heart developmental defects and died shortly after birth. Interestingly, the fetal livers of these mice demonstrated greater apoptosis of pro-B cells. Conversely, the overexpression of the miR-17-92 cluster in normal B-cell precursors can produce Bcell malignancies. The Croce laboratory and others have found that specific miRNAs appear to be causally related to chronic lymphocytic leukemia (miRNAs 15a and 16-1 and miR29a). Other miRNAs, such as let-7, exert a strong antiproliferative and tumor suppressive effect on various oncogenes, including myc, myb, and ras expression, and are downregulated or deleted in most cancers (reviewed in [6] ). Restoration of their activity reverses the malignant behavior of lymphoid, lung, and neuroblastoma tumor cells.
Because miRNA misregulation affects gene expression, and thus development and disease progression, miRNAs are considered candidate targets for therapeutic intervention. Overexpressed miRNAs can be inhibited by antimiRs, which are complementary oligonucleotides that can bind to miRNAs and block their function. These 21-to 22-nucleotide RNAs are easily synthesized, but are susceptible to nuclease digestion in the plasma and do not readily cross the cell membrane. Fortunately, only small amounts of inhibitory nucleotide are required inside the cell. Efforts to deliver and stabilize anti-miRs are focusing on the use of liposomes or nanoparticles, coupling to peptides, or stabilizing oligonucleotides by chemical modification (such as 2Ј-0-methylation or 2Ј-4Ј linkage) of its sugar phosphate backbone. The 2Ј-4Ј linked (Locked Nucleic Acid) modification by Santaris Pharma of Denmark has particular promise in that it markedly increases the affinity of the molecule for binding to mRNA or miRNA. Each of these various species of inhibitory nucleotides may be targeted to tumor cells with monoclonal antibodies or affinity peptides. Thus, a workable technology for targeting miRNAs is currently evolving, and at last count 10 clinical trials of such molecules had begun in cancer and in other diseases. The replacement of deleted or underexpressed miRNAs is also possible but represents an even bigger challenge, and may require the use of viral vectors to bring new DNA into the cell, coding for the missing miRNA.
The further implications of this rapidly evolving story for cancer diagnosis and for understanding cancer inheritance are profound. miRNAs may explain the inheritance of cases of familial cancers, such as breast or colon cancer, currently not ascribable to known full-length genes. Dissecting the biology of key miRNAs will undoubtedly point to new mechanisms that contribute to a host of important cell processes, including malignant transformation and progression. Profiling of miRNA is certain to distinguish subsets of human tumors not previously appreciated, and could well become a most important diagnostic, predictive, and prognostic tool, in that each miRNA influences the translation of multiple messages and complex pathways. Indeed, the miRNAs represent a new level of inherited biology, not previously appreciated, but certain to gain importance for cancer doctors and researchers. There is nothing micro about these Napoleons of cell biology (Fig. 2) .
